MilliporeSigma Launches Viresolve Barrier Capsule Filters to Protect Against Bioreactor Contamination

  • Upstream virus filter specifically designed to filter cell culture media
  • Protects bioreactor against a broad range of contaminants, including viruses, mycoplasma and bacteria
  • Easily scalable from preclinical through commercial manufacturing

Burlington, Massachusetts, February 13, 2018 – MilliporeSigma today introduced Viresolve® Barrier capsule filters to reduce the risk of bioreactor contamination.  Viresolve® Barrier filters are designed to remove viruses, mycoplasma and bacteria from cell culture media.

Viresolve® Barrier filters are a key component of MilliporeSigma’s Viral Safety Assurance Program to mitigate the risk of viral contamination in upstream bioprocesses and minimize the potential impact on drug supply and patient safety. The Viral Safety Assurance Program takes a holistic approach to viral safety, offering solutions to prevent viruses from entering upstream processes, detect viruses in cells, raw materials and process intermediates and remove viruses in downstream processes. 

“Viral contamination is a constant process threat,” said Andrew Bulpin, Head of the Process Solutions business area at MilliporeSigma. “One viral particle has the potential to initiate a bioreactor contamination. Our new Viresolve® Barrier filters reduce the risk of bioreactor contaminations that cause process downtime, costly investigations and possible drug supply disruptions that could impact patients.”

Scalable from bench through commercial manufacturing, Viresolve® Barrier filters offer high flux and high capacity virus filtration to ensure productivity, without impacting cell culture performance or protein quality attributes. Available now in sizes up to one square meter, including scalable micro filters for process development, these capsule filters are easy to implement directly in front of the bioreactor or into a media storage container.

The Viresolve® Barrier filter is the latest addition to the Viresolve® portfolio, now offering solutions for virus filtration in both upstream and downstream applications.

MilliporeSigma’s Process Solutions business area provides the industry’s most comprehensive portfolio of high quality products and services for biopharmaceutical manufacturing.

For more information on Viresolve® Barrier capsule filters visit For additional information on MilliporeSigma’s Viral Safety Assurance Program, visit Visit an M Lab™ Collaboration Center to learn more about Viresolve Barrier® capsule filters and explore MilliporeSigma’s Viral Safety Assurance Program.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15 billion in 2016. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Your Contact Karen Tiano +1 978 495 0093

290 Concord Road
Billerica, MA 01821 USA

Contact: Karen Tiano
+1 978 495 0093


Back to news